Alkermes shares surge after settlement with Teva on alcohol dependence treatment
Shares of Alkermes PLC (ALKS) jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Teva Pharmaceuticals USA Inc. (TEVA.TV) relating to Vivitrol, a treatment for alcohol and opioid dependence. The settlement agreement, which will be submitted for regulatory review, gives Teva a license to market a generic version of Vivitrol in the U.S. starting in early 2027, Alkermes said in a release. The settlement "lifts a key overhang" on the stock, and the 2027 generic entry date improves Alkermes' odds of hitting certain profitability targets for 2024 and 2025, Mizuho Securities analyst Uy Ear said in a note Wednesday. Alkermes shares have gained 14.5% in the year to date, while the S&P 500 has gained 17.4%. Teva's American depositary receipts were little changed Wednesday morning and have gained 6.8% in the year to date.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-30-23 1128ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy